Ocuphire Pharma Inc R3X1-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 05/20/22 CEST
1.88quote price arrow down-0.01 (-0.66%)
52 week range
1.73 - 7.00
Loading...
  • Open1.92
  • Day High1.92
  • Day Low1.81
  • Prev Close2.44
  • 52 Week High7.00
  • 52 Week High Date06/30/21
  • 52 Week Low1.73
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap38.62M
  • Shares Out19.21M
  • 10 Day Average Volume447.55
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-41.22

KEY STATS

  • Open1.92
  • Day High1.92
  • Day Low1.81
  • Prev Close2.44
  • 52 Week High7.00
  • 52 Week High Date06/30/21
  • 52 Week Low1.73
  • 52 Week Low Date05/12/22
  • Market Cap38.62M
  • Shares Out19.21M
  • 10 Day Average Volume447.55
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-41.22

RATIOS/PROFITABILITY

  • EPS (TTM)-1.33
  • P/E (TTM)-1.41
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ocuphire Pharma Inc

There is no recent news for this security.

Profile

MORE
Ocuphire Pharma, Inc. is an ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances...
Cam Gallagher
Independent Chairman of the Board
Mina Sooch
President, Chief Executive Officer, Vice Chairman of the Board, Treasurer
Amy Rabourn
Principal Accounting Officer, Vice President of Finance
Address
37000 Grand River Ave., Suite 120
Farmington Hills, MI
48335
United States